Literature DB >> 35583203

Sirtuin modulators: past, present, and future perspectives.

Francesco Fiorentino1, Nicola Mautone1, Martina Menna1, Francesca D'Acunzo2, Antonello Mai1,3, Dante Rotili1.   

Abstract

Sirtuins are NAD+-dependent protein lysine deacylase and mono-ADP ribosylases present in both prokaryotes and eukaryotes. The sirtuin family comprises seven isoforms in mammals, each possessing different subcellular localization and biological functions. Sirtuins have received increasing attention in the past two decades given their pivotal functions in a variety of biological contexts, including cytodifferentiation, transcriptional regulation, cell cycle progression, apoptosis, inflammation, metabolism, neurological and cardiovascular physiology and cancer. Consequently, modulation of sirtuin activity has been regarded as a promising therapeutic option for many pathologies. In this review, we provide an up-to-date overview of sirtuin biology and pharmacology. We examine the main features of the most relevant inhibitors and activators, analyzing their structure-activity relationships, applications in biology, and therapeutic potential.

Entities:  

Keywords:  aging; cancer; drug discovery; epigenetics; metabolism; neurodegeneration; protein lysine deacylation; sirtuin modulators; sirtuins

Mesh:

Substances:

Year:  2022        PMID: 35583203      PMCID: PMC9185222          DOI: 10.4155/fmc-2022-0031

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   4.767


  146 in total

1.  An acetylome peptide microarray reveals specificities and deacetylation substrates for all human sirtuin isoforms.

Authors:  David Rauh; Frank Fischer; Melanie Gertz; Mahadevan Lakshminarasimhan; Tim Bergbrede; Firouzeh Aladini; Christian Kambach; Christian F W Becker; Johannes Zerweck; Mike Schutkowski; Clemens Steegborn
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

2.  X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.

Authors:  Ling-Ling Yang; Hua-Li Wang; Lei Zhong; Chen Yuan; Si-Yu Liu; Zhu-Jun Yu; Sha Liu; Yu-Hang Yan; Chengyong Wu; Yuxi Wang; Zhouyu Wang; Yamei Yu; Qiang Chen; Guo-Bo Li
Journal:  Eur J Med Chem       Date:  2018-06-19       Impact factor: 6.514

3.  1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells.

Authors:  Sergio Valente; Paolo Mellini; Francesco Spallotta; Vincenzo Carafa; Angela Nebbioso; Lucia Polletta; Ilaria Carnevale; Serena Saladini; Daniela Trisciuoglio; Chiara Gabellini; Maria Tardugno; Clemens Zwergel; Chiara Cencioni; Sandra Atlante; Sébastien Moniot; Clemens Steegborn; Roberta Budriesi; Marco Tafani; Donatella Del Bufalo; Lucia Altucci; Carlo Gaetano; Antonello Mai
Journal:  J Med Chem       Date:  2016-01-05       Impact factor: 7.446

4.  Nepsilon-thioacetyl-lysine: a multi-facet functional probe for enzymatic protein lysine Nepsilon-deacetylation.

Authors:  David G Fatkins; Andrew D Monnot; Weiping Zheng
Journal:  Bioorg Med Chem Lett       Date:  2006-05-12       Impact factor: 2.823

5.  Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.

Authors:  Jill C Milne; Philip D Lambert; Simon Schenk; David P Carney; Jesse J Smith; David J Gagne; Lei Jin; Olivier Boss; Robert B Perni; Chi B Vu; Jean E Bemis; Roger Xie; Jeremy S Disch; Pui Yee Ng; Joseph J Nunes; Amy V Lynch; Hongying Yang; Heidi Galonek; Kristine Israelian; Wendy Choy; Andre Iffland; Siva Lavu; Oliver Medvedik; David A Sinclair; Jerrold M Olefsky; Michael R Jirousek; Peter J Elliott; Christoph H Westphal
Journal:  Nature       Date:  2007-11-29       Impact factor: 49.962

6.  An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease.

Authors:  Sigurd D Süssmuth; Salman Haider; G Bernhard Landwehrmeyer; Ruth Farmer; Chris Frost; Giovanna Tripepi; Claus A Andersen; Marco Di Bacco; Claudia Lamanna; Enrica Diodato; Luisa Massai; Daniela Diamanti; Elisa Mori; Letizia Magnoni; Jens Dreyhaupt; Karin Schiefele; David Craufurd; Carsten Saft; Monika Rudzinska; Danuta Ryglewicz; Michael Orth; Sebastian Brzozy; Anna Baran; Giuseppe Pollio; Ralph Andre; Sarah J Tabrizi; Borje Darpo; Goran Westerberg
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

7.  Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.

Authors:  Chi B Vu; Jean E Bemis; Jeremy S Disch; Pui Yee Ng; Joseph J Nunes; Jill C Milne; David P Carney; Amy V Lynch; Jesse J Smith; Siva Lavu; Philip D Lambert; David J Gagne; Michael R Jirousek; Simon Schenk; Jerrold M Olefsky; Robert B Perni
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

8.  Crystallographic structure of a small molecule SIRT1 activator-enzyme complex.

Authors:  Han Dai; April W Case; Thomas V Riera; Thomas Considine; Jessica E Lee; Yoshitomo Hamuro; Huizhen Zhao; Yong Jiang; Sharon M Sweitzer; Beth Pietrak; Benjamin Schwartz; Charles A Blum; Jeremy S Disch; Richard Caldwell; Bruce Szczepankiewicz; Christopher Oalmann; Pui Yee Ng; Brian H White; Rebecca Casaubon; Radha Narayan; Karsten Koppetsch; Francis Bourbonais; Bo Wu; Junfeng Wang; Dongming Qian; Fan Jiang; Cheney Mao; Minghui Wang; Erding Hu; Joe C Wu; Robert B Perni; George P Vlasuk; James L Ellis
Journal:  Nat Commun       Date:  2015-07-02       Impact factor: 14.919

9.  MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer.

Authors:  Jia-Lin Shang; Shao-Bo Ning; Ying-Yi Chen; Tian-Xiang Chen; Jian Zhang
Journal:  Acta Pharmacol Sin       Date:  2020-06-15       Impact factor: 6.150

10.  Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors.

Authors:  Sumit S Mahajan; Michele Scian; Smitha Sripathy; Jeff Posakony; Uyen Lao; Taylor K Loe; Vid Leko; Angel Thalhofer; Aaron D Schuler; Antonio Bedalov; Julian A Simon
Journal:  J Med Chem       Date:  2014-04-15       Impact factor: 7.446

View more
  1 in total

Review 1.  Therapeutic Potential and Activity Modulation of the Protein Lysine Deacylase Sirtuin 5.

Authors:  Francesco Fiorentino; Carola Castiello; Antonello Mai; Dante Rotili
Journal:  J Med Chem       Date:  2022-07-08       Impact factor: 8.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.